Table 3

Study outcomes of IGABT for patients with primary vaginal cancer

	Years of inclusion	N	Median FU (months)	Dose to D90 CTV-T_HR (Gy)	2y-LC (%)	2y-DSS (%)	2y-OS (%)	Morbidity (%)
Dimopoulos et al 27	1999–2006	13	43	86	92*	NA	85*	23
Fokdal et al 28	2005–10	9	18	82	92†	59†	74†	4
Huertas et al 29	2004–16	27	40	73	82	75	91	15
Gebhardt et al 30	2011–16	16	39	77	93‡	64‡	67‡	3
Manuel et al 31	1973–2014	47	24	81	93	86	82	2
Lee et al 32	2005–11	10	17	74	86	60	62	13
Westerveld et al 33	2001–16	148	29	80	86	73	79	17